氯胺酮与羟去甲氯胺酮作为治疗阿片使用障碍的新型药物疗法
本综述讨论阿片使用障碍(OUD)现状,指出现有药物虽可救命但未能充分处理负性情绪与认知损害,导致停药多年后仍高复发。文章综合临床前与临床研究,评估氯胺酮及其代谢物作为OUD新型治疗策略的潜力,并探讨其分子靶点与疗效的关系。总体证据显示氯胺酮及其代谢物可有效调节OUD相关病理生理过程,提示其在OUD治疗及防止戒断期恢复阿片使用方面具有前景。
要点
- 现有OUD药物未能充分处理负性情绪与认知损害,停药多年后仍高复发。
- 综述综合临床前与临床研究,评估氯胺酮及其代谢物治疗OUD的潜力。
- 证据显示氯胺酮及其代谢物可调节OUD相关病理生理过程,提示治疗前景。
核心结论
- 现有证据表明氯胺酮及其代谢物可有效调节OUD中受影响的病理生理过程,提示其在OUD治疗及防止戒断期恢复阿片使用方面具有前景。
研究设计与样本
- 本综述综合讨论评估氯胺酮及其代谢物作为OUD潜在新型治疗策略的临床前与临床研究,并分析其分子靶点与潜在效应及治疗结局的相关证据。
主要发现
- 证据支持氯胺酮作为OUD治疗候选药物,包括管理急性戒断躯体症状、长期阿片戒断期负性情绪及预防恢复非医疗使用阿片。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing high levels of opioid use and related fatalities. Although currently prescribed medications for OUD are considered lifesaving, they inadequately address negative affect and cognitive impairment, resulting in high relapse rates to nonmedical opioid use even years after drug cessation (protracted abstinence). Evidence supports the notion that ketamine, an anesthetic and rapid-acting antidepressant drug, holds promise as a candidate for OUD treatment, including the management of acute withdrawal somatic symptoms, negative affect during protracted opioid abstinence, and prevention of retaking nonmedical opioids. In this review, we comprehensively discuss preclinical and clinical research that has evaluated ketamine and its metabolites as potential novel therapeutic strategies for treating OUD. Furthermore, we examine evidence that supports the relevance of the molecular targets of ketamine and its metabolites in relation to their potential effects and therapeutic outcomes in OUD. Overall, existing evidence demonstrates that ketamine and its metabolites can effectively modulate pathophysiological processes affected in OUD, suggesting a promising therapeutic role in the treatment of OUD and the prevention of return to opioid use during abstinence.
引用
- Onisiforou A, Michael A, Apostolakis M, et al. Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders. Biol Psychiatry. 2024. PMID: 39293647. doi:10.1016/j.biopsych.2024.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。